Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia
| Autor: | Swen-Olof Andersson, Heather Payne, Kevin Carroll, Peter van Erps, Teuvo L.J. Tammela, Cees van de Beek, Thomas Morris, Pär Lodding, August Bakke, Christopher J. Tyrrell, Louis Goedhals, Tom A. Boon |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Bicalutamide medicine.medical_treatment Urology Breast pain Pain Electrons Tosyl Compounds Prostate cancer Breast Diseases Double-Blind Method Multicenter trial Nitriles medicine Confidence Intervals Humans Radiology Nuclear Medicine and imaging Anilides Breast skin and connective tissue diseases Aged Aged 80 and over Radiation business.industry Incidence (epidemiology) Prostatic Neoplasms Androgen Antagonists Middle Aged medicine.disease Surgery Radiation therapy Oncology Tolerability Gynecomastia medicine.symptom business medicine.drug |
| Zdroj: | International journal of radiation oncology, biology, physics. 60(2) |
| ISSN: | 0360-3016 |
| Popis: | To evaluate the efficacy and tolerability of prophylactic breast irradiation in reducing the incidence and severity of bicalutamide-induced gynecomastia and breast pain.In all, 106 men with prostate cancer (T1b-T4/Nx/M0) and no current gynecomastia/breast pain were enrolled in this randomized, sham-controlled, double-blind, parallel-group multicenter trial. Patients received either a single dose of electron beam radiotherapy (10 Gy) or sham radiotherapy. Bicalutamide (Casodex) 150 mg/day was administered for 12 months from the day of radiotherapy. Every 3 months, patients underwent physical examination and questioning about gynecomastia and breast pain.The incidence of investigator-assessed gynecomastia was significantly lower with radiotherapy vs. sham radiotherapy (52% vs. 85%; odds ratio [OR], 0.13; 95% confidence interval [CI], 0.04, 0.38; p0.001); direct questioning showed similar results. Fewer radiotherapy patients had/=5 cm gynecomastia (measured by calipers; 11.5% vs. 50.0% for sham radiotherapy), and fewer cases were moderate-to-severe in intensity (21% vs. 48%). Similar proportions of radiotherapy and sham radiotherapy patients experienced breast pain (83% vs. 91%; OR, 0.25; 95% CI, 0.05, 1.27; p = 0.221); patients receiving radiotherapy experienced some reduction in its severity (OR, 0.44; 95% CI, 0.20, 0.97; p = 0.0429).Prophylactic breast irradiation is an effective and well-tolerated strategy for prevention of bicalutamide-induced gynecomastia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|